Printer Friendly

SMITHKLINE BEECHAM CLINICAL LABORATORIES BREAKS GROUND FOR NEW FACILITY IN FARMINGTON HILLS

 FARMINGTON HILLS, Mich., April 12 /PRNewswire/ -- Officials of SmithKline Beecham Clinical Laboratories (SBCL) today broke ground for a new facility in Country Club Industrial Park in Farmington Hills, which will be more than triple the size of its current laboratory on Indoplex Circle.
 "Our expansion here is proof of the SmithKline Beecham Clinical Laboratories' commitment to build our business in the greater Michigan area," said W. Vickery Stoughton, president of Philadelphia-based SBCL. "Our need for a significantly expanded space in turn shows that our services are required by increasing numbers of Michigan's medical community and businesses."
 Set on seven-and-a-half acres, the new SBCL facility will initially consist of 35,000 square feet, which, according to Vivian Kermon, general manager, is expandable to 50,000 square feet. "Service to our customers will be even better with faster turnaround time and increased capabilities," Kermon said. "Because our new building will be within four-and-a-half miles of our current location, we do not anticipate any transportation problems for our 150 employees."
 "The state-of-the-art facility is expected to be completed by fall," said Kermon. Cunningham-Limp is developing the site for SBCL. Farmington Hills is northwest of Detroit in southwestern Oakland County, with a population of 10,170.
 SmithKline Beecham Clinical Laboratories is a unit of SmithKline Beecham. SmithKline Beecham, one of the world's leading healthcare companies, discovers, develops, manufactures and markets human and animal pharmaceuticals, over-the-counter medicines, as well as clinical laboratory testing services.
 -0- 4/12/93
 /CONTACT: Tobey Dichter of SmithKline Beecham Clinical Laboratories, 215-962-7511, or 800-877-7478, or home, 215-922-1633/
 (SBH)


CO: SmithKline Beecham Clinical Laboratories ST: Michigan IN: MTC SU:

SM-OS -- NY049 -- 4821 04/12/93 13:59 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 12, 1993
Words:277
Previous Article:'IDEAL' DRUGS FOR CARDIOVASCULAR DISEASES TO BE MODELED IN RESEARCH PROGRAM BY DECISION RESOURCES
Next Article:ENVIRONMENTAL CHEMICALS ACQUIRES R&M SPECIALTY PRODUCTS
Topics:


Related Articles
SMITHKLINE BEECHAM CLINICAL LABORATORIES ESTABLISHES BELGIUM FACILITY
SMITHKLINE BEECHAM CLINICAL LABORATORIES COMPLETES PURCHASE AGREEMENT FOR ALLIED CLINICAL LABORATORIES' SOUTHERN CALIFORNIA CORE OPERATIONS
ALAIN GOMEZ RESIGNS FROM SMITHKLINE BEECHAM BOARD OF DIRECTORS
SIR CHRISTOPHER HOGG ELECTED TO SMITHKLINE BEECHAM BOARD OF DIRECTORS
CORPORATE HEALTH CARE 'REPORT CARD' INTRODUCED BY SMITHKLINE BEECHAM CLINICAL LABORATORIES
SMITHKLINE BEECHAM CLINICAL LABORATORIES OPENS NEW MANHATTAN LABORATORY
SMITHKLINE BEECHAM CLINICAL LABORATORIES RETAINS LEESBURG LOCATION
SMITHKLINE BEECHAM INTRODUCES NEW DEVICE TO ENHANCE DRUG TESTING SECURITY
SMITHKLINE BEECHAM ANNOUNCES CONTINUED DECLINE IN WORKPLACE POSITIVE DRUG TESTS
SMITHKLINE BEECHAM CLINICAL LABORATORIES AND SMI FORM STRATEGIC ALLIANCE

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters